IP Library Granted Patent US 10,479,813
Granted Patent B2
US 10,479,813 · App. 16/251,750 · Granted Nov 19, 2019

Utility of nematode small molecules

Inventors: Andrea Choe (Pasadena, CA); Paul W. Sternberg (San Marino, CA); Frank C. Schroeder (Ithaca, NY); Stephan H. Von Reuss (Jena, DE)
Assignees: California Institute of Technology; Boyce Thompson Institute for Plant Research
C07H15/04A01N37/36A01N43/16A01N43/38A01N63/02A61K31/454A61K31/7028C07H15/08C07H15/10C07H15/18C07H15/26C07D309/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,479,813
App. No.
16/251,750
Granted
Nov 19, 2019
Kind
B2
Abstract

The present invention relates to methods of treating immune disorders and/or inflammation using certain modulator compounds. In one embodiment, the present invention provides a method of treating an immune and inflammatory disorders disorder by administering a composition comprising a therapeutically effective dosage of an ascaroside compound, or a mixture of ascaroside compounds, or a mixture containing at least one ascaroside.

Claims (39)

1. A method of reducing eosinophils (eos) or lymphocytes (lym), or both, in a subject, comprising:

administering a therapeutically effective dosage of a composition to the subject, thereby reducing eos or lym, or both, in the subject,

wherein the composition comprises a pharmaceutically acceptable carrier and a compound of Formula (I)

wherein

R 1 is, independently for each occurrence, hydrogen or alkyl;

R 1′ is, independently for each occurrence, hydrogen or alkyl;

X is C(R 1 ) 2 ;

X 1 is cis- or trans-C(R 1 )═C(R 1 );

n1, n2, and n3 are each independently an integer of 0 to 30, inclusive;

n4 is an integer of 1 to 30, inclusive;

the sum of n1, each n2, and each n3 is 1 to 30, inclusive;

R 3 is hydrogen or alkyl;

R 4 is hydrogen or alkyl;

R 5′ is hydrogen, alkyl, halogen, —OR 6 , or —N(R 6 ) 2 ;

R 5 is —OR 6 or —N(R 6 ) 2 ; and

R 6 is independently alkyl, alkenyl, aryl, or heteroaryl, wherein the alkyl, alkenyl, aryl, or heteroaryl is optionally substituted,

or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein R 3 is hydrogen.

3. The method of claim 1 , wherein R 4 is hydrogen.

4. The method of claim 1 , wherein R 5′ is alkyl.

5. The method of claim 1 , wherein R 5 is OR 6 .

6. The method of claim 1 , wherein the compound of Formula (I) is a compound of Formula (Ia):

wherein

R 1a is hydrogen or methyl;

n is an integer from 0 to 6, inclusive;

represents a single bond or a double bond; and

R 5a is —OR 6 ,

or a pharmaceutically acceptable salt thereof.

7. The method of claim 6 , wherein R 1a is methyl.

8. The method of claim 6 , wherein n is an integer from 0 to 4, inclusive.

9. The method of claim 1 , thereby reducing mucus production in the subject.

10. The method of claim 1 , wherein the subject is a human.

11. The method of claim 1 , wherein the subject is selected from primates, humans, equines, horses, cattle, cows, swine, sheep, rodents, rats, pets, dogs, and guinea pigs.

12. The method of claim 1 , wherein the method is a method of treating acne vulgaris, asthma, an autoimmune disease, celiac disease, chronic prostatitis, glomerulonephritis, hypersensitivity, inflammatory bowel disease, pelvic inflammatory disease, reperfusion injury, rheumatoid arthritis, sarcoidosis, transplant rejection, vasculitis, interstitial cystitis, lupus, scleroderma, hemolytic anemia, type one diabetes, Graves' disease, multiple sclerosis, Goodpasture's syndrome, pernicious anemia, myopathy, seasonal allergy, mastocytosis, perennial allergy, anaphylaxis, food allergy, allergic rhinitis, atopic dermatitis, or autism.

13. The method of claim 1 , wherein the method is a method of reducing eos in the subject.

14. The method of claim 1 , wherein the method is a method of reducing lym in the subject.

15. The method of claim 1 , wherein the method is a method of reducing eos and lym in the subject.

16. The method of claim 1 , wherein the method is a method of treating an inflammatory disorder, an autoimmune disorder, or both.

17. The method of claim 1 , wherein method is a method of treating asthma, inflammatory bowel disease, rheumatoid arthritis, or multiple sclerosis.

Assignments (5)
CONFIRMATORY LICENSE Recorded Oct 12, 2022
From: BOYCE THOMPSON INST FOR PLANT RESEARCH
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 061646/0749 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 3, 2019
From: STERNBERG, PAUL W.
To: CALIFORNIA INSTITUTE OF TECHNOLOGY
Reel/Frame 048777/0955 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2019
From: CHOE, ANDREA
To: CALIFORNIA INSTITUTE OF TECHNOLOGY
Reel/Frame 048626/0132 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2019
From: SCHROEDER, FRANK C.
To: BOYCE THOMPSON INSTITUTE FOR PLANT RESEARCH
Reel/Frame 048628/0126 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2019
From: VON REUSS, STEPHAN HEINRICH
To: BOYCE THOMPSON INSTITUTE FOR PLANT RESEARCH
Reel/Frame 048628/0140 →
Continuity (7)
Continuation 15833474 · Dec 6, 2017
Continuation 14237795
Provisional Application 61620331 · Apr 4, 2012
Provisional Application 61620343 · Apr 4, 2012
Provisional Application 61620348 · Apr 4, 2012
Provisional Application 61521295 · Aug 8, 2011
Related Publication 20190153014A1 · May 23, 2019
Cited By (1)
US 12,473,323